CN1438238A - Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof - Google Patents
Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof Download PDFInfo
- Publication number
- CN1438238A CN1438238A CN03103266A CN03103266A CN1438238A CN 1438238 A CN1438238 A CN 1438238A CN 03103266 A CN03103266 A CN 03103266A CN 03103266 A CN03103266 A CN 03103266A CN 1438238 A CN1438238 A CN 1438238A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- hepatitis
- peptide
- present
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 120
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 7
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 7
- 241000700605 Viruses Species 0.000 title abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 67
- 229920001184 polypeptide Polymers 0.000 claims abstract description 66
- 239000003814 drug Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 13
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 13
- 108090000978 Interleukin-4 Proteins 0.000 claims abstract description 13
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 8
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 8
- 239000002157 polynucleotide Substances 0.000 claims abstract description 8
- 208000005176 Hepatitis C Diseases 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 102000004127 Cytokines Human genes 0.000 description 19
- 108090000695 Cytokines Proteins 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 17
- 101710176384 Peptide 1 Proteins 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000013642 negative control Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 102000004388 Interleukin-4 Human genes 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000011160 research Methods 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 6
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- 108700006884 Hepatitis C virus HVR1 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000799 fusogenic effect Effects 0.000 description 4
- -1 hydrosulfate Chemical class 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000122128 Hepatitis C virus genotype 2 Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 101100198353 Mus musculus Rnasel gene Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000001457 metallic cations Chemical class 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention refers to a polypeptide containing synthetical peptide in high-variable region 1 of third hepatitis virus or a salt which its drugs can accept, especially a polypeptide containing synthetical peptide: GQTYTSG or a salt which its drugs can accept, having the function of guiding cell gene r-IFN, IL-4 and IL-10 and producing antibody. The invention also refers to the application of the polypeptide to make up medicament which cures and/or prevent third hepatitis, as well as combination of medicine curing third hepatitis, bacterin and polynucleotide coding the polypeptide.
Description
Invention field
The present invention relates to biology field.Relate in particular to a kind of polypeptide or acceptable salt of its medicine that contains hepatitis c virus hypervariable region 1 synthetic peptide, this polypeptide treats and/or prevents the application of the medicament of hepatitis C as preparation, and contains pharmaceutical composition, the vaccine of this polypeptide, the polynucleotide of this polypeptide of encoding.
Background technology
Viral hepatitis is a class seriously disease of harm humans health, its pathogenic agent be a class formation different have a liking for liver venereal disease poison, up to now, the hepatitis virus that has been found that has 7 types, and they are respectively HAV, HBV, HCV, HDV, HEV and possible TTV and HGV.Study clearly, HCV is inferior burst of RNA viruses of strand, and chain is about 9.4kb, contains one and almost crosses over whole genome, coding 3011 or 3010 amino acid whose single ORF.Hepatitis C by HCV causes once was called as " blood transfusion property non-A non-B hepatitis " the earliest, but later studies have shown that, hepatitis C is not only propagated by the blood transfusion mode, and alternate manner such as digestive tube, property contact etc. all can cause the propagation of hepatitis C.At present, the whole world is nearly to surpass the infected of 100,000,000, and wherein approximately patient's course of disease of 50%-90% transfers to chronicly, in these chronic infections, is respectively 8-46% and 11-19% and develops into liver cirrhosis and hepatocellular carcinoma.
The major cause of the easy chronicity of hepatitis C is because the high aberration rate of hepatitis C virus under the immunoselection effect, forms the height variation of hepatitis c virus hypervariable region 1 (HVR1 district) gene, to escape immunosurveillance.Report shows, with the antigen section, contains important neutrality epitope during HVR1 is also main, can induce the host to produce neutrality antibody.Therefore illustrate HVR1 in and the variation law of epitope and these epitopes, help the development of protective polypeptide and gene vaccine, be the key of vaccine research.The inventor is through a large amount of research, the variation of finding Chinese HCV is not a completely random, has certain conservative property, certain amino acid whosely has a specific probability each site, and mostly amino acid whose sudden change is to have between the amino acid of similar physico-chemical property, the existence that this shows HCV has certain biology restriction, since the variation of hypervariable region has certain rules, the conservative site that the inventor has proposed Chinese II/III type HCV～HVR1 district is to constitute antigenic basic framework.There are some researches show in addition between the polypeptide of anti-HCV～HVR1 that different HVR1 sequences are induced has very strong cross reaction, and also pointing out has conservative epitope in the local area.
At present, it be unclear that for the hepatitis C virus mechanism of causing a disease, also really not effective methods of treatment and vaccine are to prevent its further propagation, the permanently effective rate of the normal Interferon, rabbit that uses only is 20% clinically now, research and development reduces the HCV infection rate, and the HCV vaccine that alleviates the virus replication amount is to press for the work of finishing.For HCV patient, develop more meaningful at the medicine of hepatitis C virus.
Summary of the invention
At prior art in the deficiency that prevents and/or treats aspect the hepatitis C, the invention provides a kind of contain one or more shown in SEQ ID NO.1 the synthetic peptide of aminoacid sequence: the polypeptide of GQTYTSG or the acceptable salt of its medicine, it has the function that inducing cell factor gamma-IFN, IL-4, IL-10 and antibody produce.
The present invention also provides the application of polypeptide of the present invention at the medicament of preparation treatment hepatitis C.
The present invention also provides the application of polypeptide of the present invention at the medicament of preparation prevention of hepatitis c.
The present invention also provides a kind of pharmaceutical composition that is used for the treatment of hepatitis C, and it contains polypeptide of the present invention and the pharmaceutically acceptable in case of necessity carrier or the vehicle for the treatment of significant quantity.
The present invention also provides a kind of vaccine composition, and it contains the polypeptide of the present invention of significant quantity and the Freund's complete adjuvant or the Freund's incomplete adjuvant of significant quantity.
The present invention also provides a kind of coding to contain the polynucleotide of polypeptide of the present invention.
The inventor is under study for action on the basis of state crowd hepatitis C virus II/III type hypervariable region 1 sequence variations rule, build analysis by computer mould and designed and synthesized polypeptide of the present invention, and these polypeptide have been carried out reactive research with the HCV patients serum, the research of stimulated in vitro HCV infection of PBMCs cytokine secretion, and immunogenicity and Cytokine of Serum research in the immune mouse body.
The invention provides a peptide species or the acceptable salt of its medicine, it contains the synthetic peptide of one or more aminoacid sequences shown in SEQ IDNO.1: GQTYTSG (peptide 1), and it has the function that inducing cell factor gamma-IFN, IL-4, IL-10 and antibody produce.
Shown in embodiments of the invention 2 and 4, peptide 1 shows cross reactivity and the strong ability of inducing antibody to produce widely.This explanation wherein comprises complete epitope, comprise 7 amino acid (383-389) amino acids site in conjunction with it, and this length just in time is equivalent to the length of an epitope, is exactly a hypervariable region antigen site so can infer the 383-389 amino acids.From experimental data of the present invention also as can be seen, peptide 1 is simple in structure, and biological activity is good, is a good active peptide molecule.
Shown in embodiment 2,3 and 4, polypeptide of the present invention or the acceptable salt of its medicine have the effect that inducing cell factor gamma-IFN, IL-4, IL-10 and antibody produce.Because γ-IFN mainly is Th1 excretory cytokine, is that the human immune system resists one of major cytokine of virus infection, and has considerable meaning for the removing of HCV at the cell immune response of HCV.Therefore, the present invention provides a kind of polypeptide with effect of the hepatitis C of preventing and/or treating simultaneously.
In embodiments of the invention, polypeptide of the present invention can contain one or more shown in SEQ IDNO.1 aminoacid sequence.Optional between adjacent sequence have suitable joint or do not have joint.In other words, the aminoacid sequence in the peptide molecule of the present invention shown in SEQ ID NO.1 can be chosen wantonly by suitable joint and interconnect, and forms polymer.Polypeptide of the present invention can also be connected with the disclosed polypeptide that contains synthetic peptide: GQTYTSGX of another application that the inventor submits to the same applying date, and wherein X is A or G, forms different poly-polymer.In addition, polypeptide of the present invention can also form fusion rotein with other albumen, as forming fusion rotein with bovine serum albumin, to strengthen its immunogenicity.
Polypeptide of the present invention can use separately, also can use with the acceptable salt form of medicine.
" the acceptable salt of medicine " refers to be suitable for contact with human or animal's tissue, and does not have the salt of too much toxicity, stimulation, transformation reactions etc.The acceptable salt of medicine is well known in the art.This salt can be in the final separation of polypeptide of the present invention and the process of preparing of purifying, also polypeptide and suitable organic or inorganic acid or alkali reaction can be prepared separately.Representative acid salt includes but not limited to acetate, two hexanoates, alginate, Citrate trianion, aspartate, benzoate, benzene sulfonate, hydrosulfate, butyrates, camphorate, camsilate, glycerophosphate, Hemisulphate, enanthate, hexanoate, fumarate, hydrochloride, hydrobromate, hydriodate, the 2-isethionate, lactic acid salt, maleate, mesylate, nicotinate, the 2-naphthalenesulfonate, oxalate, 3-phenylpropionic acid salt, propionic salt, succinate, tartrate, phosphoric acid salt, glutaminate, supercarbonate, tosilate and undecane hydrochlorate.The preferred acid that can be used to form drug acceptable salt is hydrochloric acid, Hydrogen bromide, sulfuric acid, phosphoric acid, oxalic acid, toxilic acid, succsinic acid and citric acid.Positively charged ion in the acceptable base addition salt of medicine includes but not limited to basic metal or alkaline-earth metal ions such as lithium, sodium, potassium, calcium, magnesium and aluminium etc., and non-toxicity quaternary ammonium cation such as ammonium, tetramethyl-ammonium, tetraethyl ammonium, methylamine, dimethyl amine, Trimethylamine, triethylamine, diethylamide, ethylamine, diethylamine, thanomin, diethanolamine, piperidines, piperazine etc.Preferred base addition salt comprises phosphoric acid salt, tris and acetate.
Polypeptide of the present invention can be synthetic by conventional solid phase synthesis process well known by persons skilled in the art.Polypeptide for example of the present invention can be by Steward and Young (Steward, J.M.and Young, J.D., Solid Phase Peptide Synthesis, 2
NdEd., Pierce Chemical Company, Rockford, I11., (1984)) method described is with Applied Biosystem synthesizer or Pioneer
TMIt is synthetic that peptide synthesizer is pressed the solid state chemistry technology.Also can synthesize a plurality of fragments earlier, connecting together then forms bigger fragment.Synthetic for solid-phase peptide, at Steward, J.M.and Young, J.D., Solid Phase Peptide Synthesis, W.H.Freeman Co. (San Francisco), 1963 and J.Meienhofer, Hormonal Proteins and Peptides, vol.2, p.46, Academic Press (New York) can find the introduction of many technology in 1973.Generally, these methods comprise the amino acid that adds one or more amino acid or due care on the peptide chain of growing up successively.Generally; first amino acid whose amino or carboxyl are protected with suitable protecting group; amino acid with protection is connected on the inertia solid phase carrier then, adds corresponding amino or carboxyl subsequently by the next amino acid in the sequence of due care under being suitable for forming the condition of amido linkage.Remove protecting group from initiate amino-acid residue then, add the next amino acid of due care in case of necessity again, so repetitive operation.After all amino acid are with correct being linked in sequence, remove any remaining protecting group and solid support in succession or simultaneously, obtain final polypeptide.By this general procedure of simple modification, may be once to becoming long-chain to add more than one amino acid.
Prepare short polypeptide of the present invention, for example peptide 1 preferable methods is that solid-phase peptide is synthetic, in a preferred embodiment of the invention, uses 413A automatic DNA synthesizer DNA (product of PE company) to prepare polypeptide of the present invention.Wherein use α amino by the amino acid of acid or the protection of alkali sensitive groups.This protecting group should be stablized under the peptide bond formation condition, removes easily again and does not destroy the peptide chain of growth, can not cause any chiral centre racemize wherein.Suitable protecting group has 9-fluorenyl methoxy carbonyl (Fmoc), tertbutyloxycarbonyl (Boc), carbobenzoxy-(Cbz) (Cbz), 2-cyano group tertbutyloxycarbonyl etc.9-fluorenyl methoxy carbonyl (Fmoc) is that synthetic peptide of the present invention is particularly preferred.Prepare that long polypeptide of the present invention is known in the art, can use the method for glutaraldehyde cross-linking, also can use the mode of genetic expression to obtain.
The present invention also provides the application of polypeptide of the present invention as the medicament of preparation treatment hepatitis C.In embodiments of the invention 3 and 4, γ-IFN, interleukin-4, interleukin-10 all have in various degree raising in human PBMC's culture supernatant and immune serum as can be seen, especially the rising of γ-IFN level is a very interesting phenomenon, because γ-IFN mainly is a Th1 excretory cytokine, be that the human immune system resists one of major cytokine of virus infection, it is by inducing the 2-5A synthetic enzyme, and then activation RNaseL, the degraded viral RNA, thus the synthetic of viral protein suppressed.According to experimental result of the present invention, polypeptide of the present invention has the ability of the cell immune response that activates certain intensity, and has considerable meaning at the cell immune response of HCV for the removing of HCV.
The invention provides a kind of pharmaceutical composition, it contains polypeptide of the present invention and the pharmaceutically acceptable in case of necessity carrier or the vehicle for the treatment of significant quantity.Pharmaceutically acceptable carrier or vehicle refer to nontoxic solid-state, semi-solid state or liquid weighting agent, thinner, lapping or other pharmaceutical adjuncts.Can pharmaceutical composition be made various formulations according to the needs of therapeutic purpose, route of administration, for example solution, liposome agent, microcapsule and other sustained release preparations.The example of carrier or vehicle comprise physiological saline, etc. ooze the combination of glucose solution, buffer saline, glycerine, ethanol and above-mentioned solution.Can in composition, add auxiliary composition as required, for example synergistic compound be arranged with polypeptide of the present invention; Protein protective agents such as human serum albumin, low molecular weight peptide, amino acid and metallic cation; Or the like.For example, the invention provides a kind of aforementioned pharmaceutical compositions, it contains polypeptide of the present invention and Al (OH)
3, contain in wherein every ml physiological saline or the neutral phosphonic phthalate buffer (PBS) just like the synthetic about 1.0-15mg of peptide (being benchmark promptly) shown in the SEQ IDNO.1 with peptide 1, contain Al (OH)
3About 0.5-2mg.Described neutral phosphonic phthalate buffer is well known in the art, the preferred about 7.2-7.4 of pH.Mentioned reagent is behind sterilising filtration, and 2ml/ ampere bottle adopts muscle injection mode during use.Aforementioned pharmaceutical compositions more preferably contains polypeptide of the present invention and Al (OH)
3, contain in wherein every ml physiological saline or the neutral phosphonic phthalate buffer (PBS) just like the synthetic about 1.0-12mg of peptide shown in the SEQ ID NO.1, Al (OH)
3About 1mg.Certainly, pharmaceutical composition also can be directly be made of the polypeptide of the present invention and the physiological saline of significant quantity, adopts the intravenous drip mode during use.
The present invention also provides the application of polypeptide of the present invention as the medicament of preparation treatment hepatitis C.Though therapy for hepatitis C is two different aspects with prevention, the cytokine and the antibody horizontal that play a role in treatment are not closely related.But in embodiments of the invention 2 and 4, also prove that peptide 1 also has the ability of inducing antibody to produce simultaneously.Especially in embodiments of the invention 4, show that peptide 1 induces corresponding production of antibodies in the mouse body, three groups of immune serums are learned results and are carried out T check, P＜0.05 with negative control group.
The present invention also provides a kind of hcv vaccine composition, and it contains the Freund's complete adjuvant or the Freund's incomplete adjuvant of polypeptide of the present invention and significant quantity.Wherein, Freund's complete adjuvant or Freund's incomplete adjuvant are that those of ordinary skills are known, can obtain by being purchased (for example GIBCOBRL company), and content also is that those of ordinary skills determine easily.In order further to improve the immunogenicity of polypeptide of the present invention, polypeptide of the present invention can further form fusogenic peptide with other albumen.For example, the fusogenic peptide that can form with bovine serum albumin with by in conjunction with the strong molecule of big immunogenicity, improves the immunogenicity of desired polypeptides.
In addition, the invention still further relates to a kind of coding contains just like the polynucleotide that synthesize the polypeptide of peptide shown in the SEQ ID NO.1.Those of ordinary skills are known, can be according to the codon of different aminoacids correspondence, definite coding contains the polynucleotide just like the polypeptide of synthetic peptide shown in the SEQ ID NO.1, certainly, because the degeneracy of codon, described polynucleotide can have different forms, preferably according to the frequency of utilization of different biometrics password, select corresponding codon.The polynucleotide sequence of polypeptide of the present invention can be DNA or RNA, and wherein DNA comprises eDNA, genomic dna and synthetic DNA, and DNA can be two strands or single stranded form, and single stranded DNA can be coding strand or noncoding strand (antisense strand).The invention provides the nucleotide sequence of code book invention peptide 1, shown in SEQ ID NO.2.
Description of drawings
Fig. 1 shows that vitro culture HCV patient breeds PBMC FACS lymphocyte classification results: wherein, Figure 1A shows that cultivating preceding HCV patient PBMC classifies; Figure 1B shows that cultivating back HCV patient PBMC classifies.
Embodiment
Embodiment 1 synthetic peptide preparation
The inventor is under study for action on the basis of state crowd hepatitis C virus II/III type hypervariable region 1 sequence variations rule, utilize Goldkey software, according to protein structure and antigenicity prediction principle, its local wetting ability and the prediction of main chain snappiness, in conjunction with some characteristics designs of the antigen peptide of HLA molecular presentation, synthetic with 413A type automatic DNA synthesizer DNA (product of PE company).
The sequence of synthetic peptide is as follows:
HCV coating district (E2)
383????????389
↑??????????↑
Peptide 1:G Q T Y T S G SEQ ID NO.1
Synthetic peptide product carries out purity through high pressure liquid chromatography (HPLC) analysis and identifies that purity adheres to specification all greater than 95%.
The synthetic peptide of embodiment 2 the present invention is with the reactivity research of hepatitis C patients serum
1. serum is originated: 30 parts of HCV antigen/antibody combination positive serums, and infect the patient who is in hospital from 302 HCV of hospital of 2000-2001 PLA at random and choose, it is positive that PCR detects serum HCV RNA90%.Control serum: take from the healthy blood donation personnel of PLA General Hospital Blood Transfusion Department, the every index of laboratory examination is all normal.Hepatitis B (HBV) patients serum is selected from PLA's 302 hospital's hepatitis B inpatients, and laboratory examination all is the hepatitis B virus surface antigen positive.
2. method
The synthetic peptide of the present invention adopts indirect ELISA: 10ug peptide 1 of the present invention with the reactive detection of patients serum, is added on (0.1M NaHCO in the alkaline coating buffer
3, 35ul; 0.1M Na
2CO
3, 15ul; DDH
2O, 50ul) bag is by the poly-third ethene capillary strip, and 4 ℃ are spent the night.Every kind of sample is done 2 multiple holes.Add 37 ℃ of sealings of 120ulFCS-PBS 2 hours.Add successively and respectively organize patients serum's (dilution in 1: 100 was hatched 1 hour for 37 ℃) and goat anti-human igg (available from magnificent biological products company) (1: 1000, hatch the same).Last every hole adds A, B liquid (Beijing Ke Wei chemical reagent work product) 50ul, puts the dark place and puts 5 minutes, detects absorbance (A) down in the 450nm wavelength.Adopt DG3022 type enzyme-linked immunosorbent assay instrument (product of PE company).
3. result
3.1 polypeptide of the present invention is as follows in conjunction with the positive findings of HCV patients serum (30 parts):
Table 1
| The peptide numbering | Positive routine number | Positive per-cent (%) |
| Peptide 1 | ????13 | ????43.3 |
| Fusogenic peptide (7 peptide 1 series connection) | ????23 | ????70 |
Wherein these 13 parts of reactions organizing among common 30 parts of patients serums are positive, and what peptide 1 was described reaches 43.3% in conjunction with per-cent.And fusogenic peptide reach 70% in conjunction with per-cent.
This polypeptide is all negative in conjunction with test-results with HBV patients serum and healthy human serum.
3.2 make table according to test-results, as follows:
Table 2 polypeptide of the present invention compares with experimental group HCV infected patient serum and negative control group normal human serum reaction result
| Group | Positive number | Negative number |
| Test group | ????13 | ????17 |
| Negative control group | ????0 | ????10 |
Between STATA software is respectively to two groups, carry out statistical analysis, chi square test P=0.011,＜0.05, two groups positive rate difference has the significance meaning.That is to say that this is combined into peptide can cause HCV infected patient sero-reaction, reactionless with the negative control group normal human serum.
Table 3 polypeptide of the present invention compares with experimental group HCV infected patient serum and HBV infected patient sero-reaction
| Group | Positive number | Negative number |
| Test group | ????13 | ????17 |
| HBV patients serum control group | ????0 | ????10 |
Between two groups, carry out statistical analysis respectively, chi square test P=0.011,＜0.01, two groups positive rate difference has the significance meaning.That is to say that this is combined into peptide can cause HCV infected patient sero-reaction, reactionless with HBV infected patient serum.
The research of embodiment 3 polypeptide stimulated in vitro HCV infection of PBMCs cytokine secretions of the present invention
1. peripheral blood cells is originated: 23 parts of HCV infect the positive blood samples and take from the patient that 302 HCV of hospital infection is in hospital, and it is positive that PCR detects serum HCV RNA90%.Serum HCV antibody positive.
2. method
2.1 the extraction of sample PBMC
Get fresh vein heparin anti-coagulating 3ml, add the dilution of equivalent Hank ' s liquid, mixing, gently be taped against on the lymphocyte separation medium liquid level with blood volume equivalent, 1500-2000rpm/min, centrifugal 30 minutes, the nebulous buffy coat of sucking-off, use Hank ' s liquid to wash twice, can obtain a large amount of lymphocytes.
2.2 cell cultures
The lymphocyte that obtains is counted at microscopically, be approximately 1*10 by every part cell count
5/ 100ul is added to the cell evenly distribute on the 96 porocyte culture plates, adds the synthetic peptide of antigen in a certain amount of (10ug/ hole), other establishes the positive control hole that the negative control hole that do not add peptide and PHA stimulate, (every kind of sample is established three multiple holes), concussion mixing, insert 37C, 5%CO
2Cultivate in the incubator, observe.Continuous microscopically observation of cell state in the culturing process, record.
2.3 the collection of culture supernatant
With the bull cell harvestor carefully with cell harvesting in test tube, 1000-rpm/min, centrifugal 10 minutes sedimentation cells are collected culture supernatant.
2.4 the detection of cytokine: adopt ELASA method (reagent source see on)
(1) except that blank well, respectively with the standard substance (100 microlitres/hole) of sample or different concns
Add in the respective aperture, seal reacting hole with the shrouding gummed paper, room temperature (20-25 ℃)
Hatched 120 minutes.
(2) wash plate 4 times.
(3) except that blank well, add detection agent working fluid (100 microlitres/hole).Use shrouding glue
Paper is sealed reacting hole, and room temperature (20-25 ℃) was hatched 60 minutes.
(4) wash plate 4 times.
(5) add substrate A, B (each 50 microlitres/hole), black out room temperature 10-30 minute.
2.5 sample fluorescent mark
(1) collects culturing cell.
(2) 2%FCS cleans twice.
(3) add fluorescence antibody 1 microlitre/10
5Cell.The lucifuge room temperature left standstill 20 minutes.
(4) 2%FCS cleans one time.
(5) add 2 milliliters of 1% Paraformaldehyde 96s, 4 ℃ of preservations.
2.6 lymphocyte classification and Detection: good sample is appearred in colony after cultivating cultivate, and utilize flow cytometer (the FACS CALIBUR of BD company type) to detect fluorescence CD4 and CD8 antibody labeling cell.
2.7 statistical method: the Stata statistical software calculates.
1 group of measurement result of peptide is carried out the t check with negative group result.Because it is uneven with negative prescription difference to measure the result of IL-4, IL-10 and γ-IFN, statistical method adopts rank test.
3. result
3.1 om observation:
The PBMC of HCV infected patient added behind the synthetic peptide second day, it is good that mirror is observed the visible cell life down, body is big, individual circle, light transmission is good, and the visual field a plurality of minicell propagation group is expired in the positive control hole as seen, the minicell propagation group that as seen experimental port is dispersed in, cultivated about 4 days, the more preceding increase of the small cell cluster that as seen is dispersed in forms tangible colony group.Negative control hole does not see that tangible colony group occurs.Patient's HBV PBL does not see colony group after adding synthetic peptide.
3.2 vitro culture HCV patient breeds PBMC FACS lymphocyte classification results
As shown in Figure 1, cultivate CD4+ cell proportion increase (on average rising 3.5%) in the proliferating-cell population lymphocyte classification of back, and CD8+ cell proportion descends (on average descending 2.9%), illustrates that proliferative cell is mainly the CD4+ cell.
3.3 cell in vitro factor secretion level changes research
No. 5 sample has proliferative response preferably to peptide 1, so its cytokine secretion level is studied over time.
The result shows: IL-4, IL-10, γ-IFN level are that the prolongation with incubation time raises.And between 48-72 after the cultivation hour, reach highest level.
3.4 cultivate cytokine levels in 72 hours the supernatant
γ-IFN detected result shows: γ-IFN secretion significantly raises, and is 32.87 (pg/ml), compares obvious rising with negative control group, difference significance (P＜0.05).
The IL-4 detected result shows: the IL-4 secretion significantly raises, and is 31.0 (pg/ml), compares obvious rising with negative control group, difference significance (P＜0.05).
The IL-10 detected result shows: the IL-10 secretion significantly raises, and is 109.2, (pg/ml), compares obvious rising with negative control group, difference significance (P＜0.05).The variation of the different patient P BMC of table 4 cytokine levels after synthetic peptide stimulates
| No. 5 | No. 8 | No. 9 | No. 13 | No. 16 | No. 20 | |
| IL-4 | ????+ | ????+ | ????+ | ????+++ | ????++ | ????+ |
| IL-10 | ????+++ | ????+++ | ????+ | ????+ | ????++ | ????+ |
| γ-IFN | ????+ | ????+ | ????+ | ????+ | ????++ | ????+ |
The research of embodiment 4 polypeptide of the present invention immunogenicity and Cytokine of Serum in the mouse body
1. laboratory animal
BALB/c mouse is available from Military Medical Science Institute's Experimental Animal Center, is 6 ages in week of male property.
2. method
2.1 immune mouse
With above-mentioned peptide 1 direct immunization mouse, every group of 5 mouse.Other establishes one group of negative control group, the synthetic peptide consumption of immunity for the first time is 50ug, Freund's complete adjuvant (GIBCOBRL company) is mixed with each 50ul equal-volume of antigenic synthetic peptide, with the abundant mixing of micro-stirrer, multi-point injection mouse insole, negative control group are only injected complete Freund's adjuvant.Carry out the immunity second time after 2 weeks, i.e. booster immunization.With same synthetic peptide amount, use Freund's incomplete adjuvant (for example GIBCOBRL company) instead, volume injected and method are the same.Immunity is impacted immunity after carrying out twice, and with the synthetic peptide of PBS 200ul dissolving 100ug, through intramuscular injection, negative control group is only injected the PBS of 200ul.For the first time and for the second time booster immunization is cut tail to mouse one day after and is got blood, and booster immunization was extractd the eyeball of mouse bloodletting after three days for the second time, collected serum and made sample.
2.2 the ELASA method is adopted in the mice serum antibody test
(1) use peptide 1 as the antigen coated poly-third ethene capillary strip, every kind of sample synthesizes the peptide consumption and uses 10ug respectively with three multiple holes, joins in the 100ul alkalescence coating buffer, and 4 ℃ are spent the night.
(2) with 120ul PBS sealing, hatched 2 hours for 37 ℃.
(3) mice serum is respectively organized in adding, and dilution in 1: 100 was hatched 1 hour for 37 ℃.
(4) every hole adds sheep anti-mouse igg 100ul (1: 1000) dilution, hatches 1 hour for 37 ℃.
(5) every hole adds A, B liquid 50ul, puts the dark place and puts 5 minutes, detects optical density(OD) (OD) value under the 450nm wavelength.
2.3 the mice serum cytokines measurement adopts the ELASA method
(1) except that blank well, the standard substance (100 microlitres/hole) with sample or different concns add in the respective aperture respectively, seal reacting hole with the shrouding gummed paper, and room temperature (20-25 ℃) was hatched 120 minutes.
(2) wash plate 4 times.
(3) except that blank well, add detection agent working fluid (100 microlitres/hole).Seal reacting hole with the shrouding gummed paper, room temperature (20-25 ℃) was hatched 60 minutes.
(4) wash plate 4 times.
(5) add substrate A, B (each 50 microlitres/hole), black out room temperature 10-30 minute.
(6) add stop buffer (50 microlitres/hole), measure OD value under the 450nm wavelength behind the mixing at once.
3. result
3.1 synthetic peptide immune effect
Table 5:450nm wavelength detects the average OD value of anti-synthetic peptide antibody correspondence down:
3.2 the mice serum cytokine levels: the result is as follows, each cytokine concentration (pg/ml) in the table 6 experiment mice serum
| The mouse numbering | OD value (serum dilution in 1: 100) |
| ????No.1 | ????0.175 |
| ????No.2 | ????0.169 |
| ????No.3 | ????0.158 |
| ????No.4 | ????0.210 |
| ????No.5 | ????0.180 |
| Average | ????0.178±0.019 |
| Negative control | ????0.025 |
| Grouping | Cytokine | ||
| ????IL-4 | ????IL-10 | ????γ-IFN | |
| Experimental group | ??29.64±4.9 | ??27.94±6.4 | ??23.46±5.9 |
| Contrast | ??2.6±0.1 | ??5.86±1.0 | ??5.9±0.2 |
Above-mentioned experimental result shows that mouse has produced tangible immune response to peptide 1.And γ-IFN, IL-4, IL-10 in the serum have raising in various degree.Especially the rising of γ-IFN level is a very interesting phenomenon, because γ-IFN mainly is a Th1 excretory cytokine, be that the human immune system resists one of major cytokine of virus infection, it is by inducing the 2-5A synthetic enzyme, and then activation RNaseL, the degraded viral RNA, thus the synthetic of viral protein suppressed.Illustrate that polypeptide of the present invention has the ability of the cell immune response that activates certain intensity, so polypeptide cause have considerable meaning at the cell immune response of HCV for the removing of HCV.
Sequence table＜110〉Cheng Yun
Infectious Inst. of PLA＜120〉hepatitis c virus hypervariable region 1 synthetic peptide and application＜130 thereof〉D0301059F＜160〉2＜170〉PatentIn version 3.1＜210〉1＜211〉7＜212〉PRT＜213〉artificial sequence＜220〉＜223〉hepatitis c virus hypervariable region 1 synthetic peptide＜400〉1Gly Gln Thr Tyr Thr Ser Gly1 5＜210〉2＜211〉21＜212〉DNA＜213〉artificial sequence＜220〉＜221〉misc_feature＜222〉(3,9,15,18,21)＜22 3〉n=u or c or a or g＜220〉＜221〉misc_feature＜222〉(6)＜223〉r=a or g＜220＜221〉misc_feature＜222〉(12)＜223〉y=u or c＜400 2gancaracnu ayacnucnga n
Claims (10)
1, contain one or more shown in SEQ ID NO.1 the synthetic peptide of aminoacid sequence: the polypeptide of GQTYTSG or the acceptable salt of its medicine, it has the function that inducing cell factor gamma-IFN, IL-4, IL-10 and antibody produce.
2, described polypeptide of claim 1 or the acceptable salt of its medicine is characterized in that it is synthetic peptide or the acceptable salt of its medicine shown in SEQ ID NO.1.
3, polypeptide as claimed in claim 1 or 2 or the acceptable salt of its medicine, it has the effect of the hepatitis C for the treatment of and/or preventing.
4, each described polypeptide of claim 1-3 is in the application of the medicament of preparation treatment hepatitis C.
5, each described polypeptide of claim 1-3 is in the application of the medicament of preparation prevention of hepatitis c.
6, a kind of pharmaceutical composition that is used for the treatment of hepatitis C, it contains each described polypeptide of claim 1-3 and the pharmaceutically acceptable in case of necessity carrier or the vehicle for the treatment of significant quantity.
7, the described pharmaceutical composition of claim 6, it contains each described polypeptide of claim 1-3 and Al (OH)
3, contain in wherein every ml physiological saline or the neutral phosphonic phthalate buffer just like synthetic peptide 1.0-15mg shown in the SEQID NO.1, contain Al (OH)
30.5-2mg.
8, the described pharmaceutical composition of claim 6, its each described polypeptide of claim 1-3 and physiological saline by significant quantity constitutes.
9, a kind of hcv vaccine composition, it contains each the described polypeptide of claim 1-3 of significant quantity and the Freund's complete adjuvant or the Freund's incomplete adjuvant of significant quantity.
10, a kind of polynucleotide of each polypeptide of claim 1-3 of encoding.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031032664A CN1194986C (en) | 2003-01-24 | 2003-01-24 | Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031032664A CN1194986C (en) | 2003-01-24 | 2003-01-24 | Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1438238A true CN1438238A (en) | 2003-08-27 |
| CN1194986C CN1194986C (en) | 2005-03-30 |
Family
ID=27673894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031032664A Expired - Fee Related CN1194986C (en) | 2003-01-24 | 2003-01-24 | Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1194986C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009127140A1 (en) * | 2008-04-18 | 2009-10-22 | Cheng Yun | 7p peptide and its derivant, the use thereof |
| JP2009538838A (en) * | 2006-06-01 | 2009-11-12 | 程云 | Peptides to prevent or treat liver damage |
| CN102178926B (en) * | 2006-06-01 | 2012-07-25 | 程云 | Peptide for preventing or treating liver damage |
| WO2014094230A1 (en) * | 2012-12-18 | 2014-06-26 | Cheng Yun | Application of sp peptide or derivative thereof in preparing drugs for preventing or treating asthma |
| WO2014121492A1 (en) * | 2013-02-07 | 2014-08-14 | Cheng Yun | Use of sp peptide or derivatives thereof for preparing drugs for lowering level of il-13 |
| CN104780930A (en) * | 2011-09-30 | 2015-07-15 | 程云 | Use of hepatitis C virus (HCV) immunogenic peptide or its derivatives in prevention or treatment of arthritis |
| WO2021098854A1 (en) * | 2019-11-21 | 2021-05-27 | 上海医药工业研究院 | Biological peptide for treating lung diseases and application thereof |
-
2003
- 2003-01-24 CN CNB031032664A patent/CN1194986C/en not_active Expired - Fee Related
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009538838A (en) * | 2006-06-01 | 2009-11-12 | 程云 | Peptides to prevent or treat liver damage |
| CN101336110B (en) * | 2006-06-01 | 2011-06-01 | 程云 | Peptides and their derivatives for preventing or treating liver damage and applications thereof |
| EP2030628A4 (en) * | 2006-06-01 | 2011-08-10 | Yun Cheng | A peptide for preventing or treating liver damage and its derivant and the use |
| CN102178926B (en) * | 2006-06-01 | 2012-07-25 | 程云 | Peptide for preventing or treating liver damage |
| WO2009127140A1 (en) * | 2008-04-18 | 2009-10-22 | Cheng Yun | 7p peptide and its derivant, the use thereof |
| CN104780930A (en) * | 2011-09-30 | 2015-07-15 | 程云 | Use of hepatitis C virus (HCV) immunogenic peptide or its derivatives in prevention or treatment of arthritis |
| CN104955469B (en) * | 2012-12-18 | 2016-12-21 | 程云 | Application of SP peptide or its derivatives in the preparation of drugs for preventing or treating asthma |
| CN104955469A (en) * | 2012-12-18 | 2015-09-30 | 程云 | Application of sp peptide or derivative thereof in preparing drugs for preventing or treating asthma |
| WO2014094230A1 (en) * | 2012-12-18 | 2014-06-26 | Cheng Yun | Application of sp peptide or derivative thereof in preparing drugs for preventing or treating asthma |
| US9605023B2 (en) | 2012-12-18 | 2017-03-28 | Yun Cheng | Application of SP peptide or derivative thereof in preparing medicines for preventing or treating asthma |
| WO2014121492A1 (en) * | 2013-02-07 | 2014-08-14 | Cheng Yun | Use of sp peptide or derivatives thereof for preparing drugs for lowering level of il-13 |
| WO2021098854A1 (en) * | 2019-11-21 | 2021-05-27 | 上海医药工业研究院 | Biological peptide for treating lung diseases and application thereof |
| EP4063378A4 (en) * | 2019-11-21 | 2024-06-19 | Shanghai Institute of Pharmaceutical Industry Co., Ltd. | Biological peptide for treating lung diseases and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1194986C (en) | 2005-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1055701C (en) | Peptide capable of inducing immune response to HIV and medicament for preventing and treating AIDS containing the peptide | |
| CN103298485B (en) | Multivalent vaccine against filariasis | |
| CN1629185A (en) | Fusion proteins of mycobacterium tuberculosis antigens and their uses | |
| CN112057613A (en) | MERS-CoV vaccine | |
| RU2323744C2 (en) | Anti-hcv vaccine | |
| Donelson et al. | How the trypanosome changes its coat | |
| CN113876938A (en) | Construction and application of fusion protein vaccine platform | |
| JP2002512800A5 (en) | ||
| CN1194986C (en) | Type-c hepatitis virus high-variation-zone 1 synthesized peptide and use thereof | |
| CN1054772A (en) | Synthetic polypeptide | |
| CN105132371B (en) | External method and the application thereof of offering, activate DC cell | |
| CN1216075C (en) | Hepatitis C virus high change region 1 synthetic peptide and its use | |
| CN102924576B (en) | Helicobacter pylori immunodominance epitope peptide and preparation method and application thereof | |
| JPH07504662A (en) | Immune stimulants for therapeutic use in immunocompromised hosts | |
| CN102406929A (en) | Co-expression molecular adjuvant enhanced bivalent foot-and-mouth disease protein engineering vaccine | |
| US20080019972A1 (en) | Method for Amplifying Therapeutic Vaccine Activity | |
| KR102211077B1 (en) | A pseudo type rabies virus vaccine using virus-like particles | |
| CN114560916A (en) | T cell epitope polypeptide KLLEQWNLV derived from SARS-CoV-2 encoding protein and application thereof | |
| CN101111227A (en) | Method for producing bioresorbable microparticles, microparticles obtained therefrom and applications thereof | |
| CN117442713B (en) | Ii-keyT cell peptide of novel coronavirus Omicron series variants and its application | |
| EA008143B1 (en) | Immunogenic formulations of variable peptidic epitopes and process for preparation thereof | |
| Khan | Medical biotechnology | |
| CN100484570C (en) | Gene vaccine against SARS virogene and its construction and use | |
| CN110922492B (en) | DC vaccine for inducing CML cellular immune response mediated by fusion peptide and CTP and preparation method thereof | |
| CN113845568B (en) | A class of polypeptides that promote broad-spectrum acquired immune responses in pigs and their applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050330 Termination date: 20190124 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |